脓毒症与危重症免疫失调共识框架
危重症综合征如脓毒症、急性呼吸窘迫综合征(ARDS)和创伤的致残率与死亡率仍高,其异质性限制了进展。SUBSPACE国际联盟通过共享转录组数据,在37个独立队列逾7074份样本中评估脓毒症现有免疫内型的重叠,构建细胞类型特异性基因表达特征以量化免疫区室失调。髓系与淋系失调在所有队列中均与疾病严重度和死亡相关,且在ARDS、创伤和烧伤患者中同样可见,提示跨危重症综合征存在保守机制。随机对照试验数据分析显示,髓系与淋系失调与SAVE-MORE试验(n=452)中阿那白滞素治疗患者、VICTAS(n=89)和VANISH(n=117)试验中糖皮质激素治疗患者的差异死亡相关。作者提出基于免疫学的细胞区室失调量化框架,可能为理解危重症免疫失调提供有预后和治疗价值的工具。
要点
- 在37个独立队列逾7074份样本中,髓系与淋系失调与脓毒症疾病严重度和死亡相关。
- 髓系与淋系失调在ARDS、创伤和烧伤患者中同样可见,提示跨危重症综合征存在保守机制。
- SAVE-MORE试验(n=452)中,髓系与淋系失调与阿那白滞素治疗患者的差异死亡相关。
- VICTAS(n=89)和VANISH(n=117)试验中,髓系与淋系失调与糖皮质激素治疗患者的差异死亡相关。
- 作者认为该免疫学框架可能为危重症免疫失调提供有预后和治疗价值的工具。
适用人群与场景
- 脓毒症患者,来自37个独立队列逾7074份样本。
- ARDS、创伤和烧伤患者,用于验证免疫失调的跨综合征保守性。
- SAVE-MORE试验(n=452)中接受阿那白滞素治疗的患者。
- VICTAS(n=89)和VANISH(n=117)试验中接受糖皮质激素治疗的患者。
研究设计与关键结果
- 研究类型为国际联盟(SUBSPACE)的转录组数据共享分析,评估脓毒症现有免疫内型重叠,样本量逾7074份、来自37个独立队列。
- 构建细胞类型特异性基因表达特征以量化免疫区室失调,髓系与淋系失调在所有队列中均与疾病严重度和死亡相关。
- 髓系与淋系失调在ARDS、创伤和烧伤患者中同样可见,提示跨危重症综合征存在保守机制。
- SAVE-MORE试验(n=452)中,髓系与淋系失调与阿那白滞素治疗患者的差异死亡相关。
- VICTAS(n=89)和VANISH(n=117)试验中,髓系与淋系失调与糖皮质激素治疗患者的差异死亡相关。
证据类型、等级与局限
- 证据类型:基于多队列转录组数据的观察性分析及随机对照试验数据的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,所提出的基于免疫学的细胞区室失调量化框架可能为理解危重症免疫失调提供有预后和治疗价值的工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Critical care syndromes such as sepsis, acute respiratory distress syndrome (ARDS) and trauma continue to have unacceptably high morbidity and mortality, with progress limited by the inherent heterogeneity within syndromic illnesses. Although numerous immune endotypes have been proposed for sepsis and critical care, the similarities and differences between these endotypes remain unclear, hindering clinical translation. The SUBSPACE consortium is an international consortium that aims to advance precision medicine in critical care through the sharing of transcriptomic data. Here, evaluating the overlap of existing immune endotypes in sepsis across >7,074 samples from 37 independent cohorts, we developed cell-type-specific gene expression signatures to quantify dysregulation within immune compartments. Myeloid and lymphoid dysregulation were associated with disease severity and mortality across all cohorts. Importantly, this dysregulation was also observed in patients with ARDS, trauma and burns, suggesting a conserved mechanism across various critical illness syndromes. Moreover, analysis of randomized controlled trial data revealed that myeloid and lymphoid dysregulation are associated with differential mortality in patients treated with anakinra in the SAVE-MORE trial (n = 452) and corticosteroids in the VICTAS (n = 89) and VANISH (n = 117) trials, underscoring their prognostic and therapeutic implications. In conclusion, our proposed immunology-based framework for quantifying cellular compartment dysregulation offers a potentially valuable tool for understanding immune dysregulation in critical illness with prognostic and therapeutic significance.
参考来源
- Moore AR, Zheng H, Ganesan A, et al. A consensus immune dysregulation framework for sepsis and critical illnesses. Nat Med. 2025. PMID: 41028543. doi:10.1038/s41591-025-03956-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。